Palatin (PTN) Q3 2025 Earnings Call May 14, 2025 11:00 AM ET Company Participants Carl Spana - Co-Founder, President, CEO & DirectorStephen Wills - CFO, COO, Secretary & Treasurer Conference Call Participants Scott Henry - Managing Director & Senior Research Analyst Operator Greetings. Welcome to Palatin's Third Quarter Fiscal Year twenty twenty five Operating Results Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. ...

Palatin (PTN) Q3 2025 Earnings Call May 14, 2025 11:00 AM ET Speaker0 Greetings. Welcome to Palatin's Third Quarter Fiscal Year twenty twenty five Operating Results Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference call is being recorded. Before we begin our remarks, I would like to remind you that statements made by Palatin are not historical facts and may be forward looking statements ...

Updated Phase 3 analyses position PL9643 as a potential first-in-class therapy achieving full symptom resolution in dry eye disease. Responder analyses demonstrated statistically significant symptom clearing (resolution) across multiple endpoints in patients treated with PL9643, compared to placebo. Six of 13 symptom endpoints showed a significantly higher percentage of patients in the PL9643 group achieving complete symptom resolution compared to placebo (p<0.05). This level of symptom clearing has not b ...